BR112023003265A2 - Inibidores de secreção de proteínas - Google Patents

Inibidores de secreção de proteínas

Info

Publication number
BR112023003265A2
BR112023003265A2 BR112023003265A BR112023003265A BR112023003265A2 BR 112023003265 A2 BR112023003265 A2 BR 112023003265A2 BR 112023003265 A BR112023003265 A BR 112023003265A BR 112023003265 A BR112023003265 A BR 112023003265A BR 112023003265 A2 BR112023003265 A2 BR 112023003265A2
Authority
BR
Brazil
Prior art keywords
protein secretion
secretion inhibitors
inhibitors
methods
protein
Prior art date
Application number
BR112023003265A
Other languages
English (en)
Inventor
Mcminn Dustin
Rao Meera
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of BR112023003265A2 publication Critical patent/BR112023003265A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

INIBIDORES DE SECREÇÃO DE PROTEÍNAS. São providos neste documento inibidores de secreção, como inibidores de Sec61, métodos para sua preparação, composições farmacêuticas relacionadas e métodos para usar os mesmos.
BR112023003265A 2020-08-31 2021-08-31 Inibidores de secreção de proteínas BR112023003265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072690P 2020-08-31 2020-08-31
PCT/US2021/048317 WO2022047347A1 (en) 2020-08-31 2021-08-31 Protein secretion inhibitors

Publications (1)

Publication Number Publication Date
BR112023003265A2 true BR112023003265A2 (pt) 2023-05-02

Family

ID=78087485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003265A BR112023003265A2 (pt) 2020-08-31 2021-08-31 Inibidores de secreção de proteínas

Country Status (16)

Country Link
US (1) US20230286973A1 (pt)
EP (1) EP4204417A1 (pt)
JP (1) JP2023539553A (pt)
KR (1) KR20230058655A (pt)
CN (1) CN116194455A (pt)
AR (1) AR123385A1 (pt)
AU (1) AU2021334388A1 (pt)
BR (1) BR112023003265A2 (pt)
CA (1) CA3190441A1 (pt)
CL (1) CL2023000582A1 (pt)
CO (1) CO2023002202A2 (pt)
IL (1) IL300736A (pt)
MX (1) MX2023002288A (pt)
PE (1) PE20231436A1 (pt)
TW (1) TW202227428A (pt)
WO (1) WO2022047347A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164250A1 (en) * 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
CN113993587A (zh) * 2019-02-28 2022-01-28 科智生命科学公司 作为蛋白分泌抑制剂的噻唑衍生物

Also Published As

Publication number Publication date
TW202227428A (zh) 2022-07-16
CO2023002202A2 (es) 2023-03-27
CN116194455A (zh) 2023-05-30
MX2023002288A (es) 2023-03-10
KR20230058655A (ko) 2023-05-03
IL300736A (en) 2023-04-01
CA3190441A1 (en) 2022-03-03
EP4204417A1 (en) 2023-07-05
PE20231436A1 (es) 2023-09-14
WO2022047347A1 (en) 2022-03-03
CL2023000582A1 (es) 2023-09-29
AR123385A1 (es) 2022-11-23
AU2021334388A1 (en) 2023-03-02
US20230286973A1 (en) 2023-09-14
JP2023539553A (ja) 2023-09-15

Similar Documents

Publication Publication Date Title
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112019002371A2 (pt) composições farmacêuticas
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
PH12020551716A1 (en) Anti-ror antibody constructs
BR112017005660A2 (pt) novos ativadores de guanilato ciclase solúvel e sua utilização
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112022008365A2 (pt) Inibidores de cd73
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
EA201791918A1 (ru) Модификация белков клеток-хозяев
CY1125043T1 (el) Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.
BR112018072699A2 (pt) determinados inibidores de proteína cinase
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
BR112023003265A2 (pt) Inibidores de secreção de proteínas